BI 01383298 is primarily utilized in pharmaceutical research and development, particularly in the field of oncology. It is being investigated for its potential as a therapeutic agent in cancer treatment, focusing on its ability to target specific molecular pathways involved in tumor growth and progression. Researchers are exploring its efficacy in inhibiting key enzymes or proteins that contribute to cancer cell survival and proliferation. Additionally, preclinical studies are underway to assess its pharmacokinetics, safety profile, and potential combination with other anticancer therapies. Its application extends to biomarker studies to identify patient populations that may benefit most from its use.